Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are rare neoplasms. They are varied in their biological and clinical behavior: most have endocrine function and they secrete peptides that cause distinct clinical syndromes, including carcinoid syndrome; many are clinically silent until late presentation. Investigation and management should be individualized for each patient, taking into consideration the natural history of the tumour and general health of the patient. Management strategies include surgery and other cytoreductive techniques for cure and palliation and medical treatment including chemotherapy and biotherapy (somatostatin analogues and alpha-inteferon) to control symptoms and tumor growth. New biological agents and peptide receptor radionuclide therapy are under investigation.
|Translated title of the contribution||Gastroenteropancreatic neuroendocrine tumors|
|Number of pages||8|
|Journal||Argomenti di Gastroenterologia Clinica|
|Publication status||Published - Jun 2008|
ASJC Scopus subject areas